Sold as Zinbryta. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Daclizumab (sold as Zinbryta), first approved May 27, 2016, with 1 new use approved and 0 published complete response letters.
| Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCTGraft Versus Host Disease, Hematologic Neoplasms · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | Recruiting | Jul 8, 2026 |
| Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive RegimenDiabetes Mellitus · City of Hope Medical Center | Phase 1 | Active, not recruiting | Jun 27, 2008 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Biogen